Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity

There is an unmet need for safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are stable and can be cost-effectively produced at large scale. Here, a biopolymer particle (BP) vaccine technology that can be quickly adapted to new and emerging variants of SARS-CoV-2 is used. Coronavirus antigen-coated BPs are described as vaccines against SARS-CoV-2. The spike protein subunit S1 or epitopes from S and M proteins (SM) plus/minus the nucleocapsid protein (N) are selected as antigens to either coat BPs during assembly inside engineered Escherichia coli or BPs are engineered to specifically ligate glycosylated spike protein (S1-ICC) produced by using baculovirus expression in insect cell culture (ICC). BP vaccines are safe and immunogenic in mice. BP vaccines, SM-BP-N and S1-ICC-BP induced protective immunity in the hamster SARS-CoV-2 infection model as shown by reduction of virus titers up to viral clearance in lungs post infection. The BP platform offers the possibility for rapid design and cost-effective large-scale manufacture of ambient temperature stable and globally available vaccines to combat the coronavirus disease 2019 (COVID-19) pandemic.

Automated summary

The biopolymer particle (BP) vaccine technology offers a promising solution to the unmet need for safe and effective SARS-CoV-2 vaccines that can be produced at large scale. These vaccines, utilizing coronavirus antigen-coated BPs, have shown safety and immunogenicity in mice and induced protective immunity in a hamster SARS-CoV-2 infection model. The BP platform enables rapid design and cost-effective manufacture of ambient temperature stable vaccines to combat the COVID-19 pandemic.